# A short course of BG9588 (anti–CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/a-short-course-of-bg9588-anti-cd40-ligand-antibody-improves-serologic-activity/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Dimitrios T. Boumpas,Richard Furie,Susan Manzi,Gabor G. Illei,Daniel J. Wallace,James E. Balow,Akshay Vaishnaw,on behalf of the BG9588 Lupus Nephritis Trial Group |
| Citations | 618 |
| DOI | 10.1002/art.10856 |
| Fields | Immunology and Microbiology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2029957805 |
| PMID | 12632425 |
| Type | article |
| Year | 2003 |

## Paper authors

- [Dimitrios T. Boumpas](https://scholariq.org/researchers/dimitrios-t-boumpas/)
- [Richard Furie](https://scholariq.org/researchers/richard-furie/)
- [Daniel J. Wallace](https://scholariq.org/researchers/daniel-j-wallace/)

## Paper primary topic

- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)

## Paper topics

- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [T-cell and B-cell Immunology](https://scholariq.org/topics/t-cell-and-b-cell-immunology/)
- [Renal Transplantation Outcomes and Treatments](https://scholariq.org/topics/renal-transplantation-outcomes-and-treatments/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.